Aprea Therapeutics, Inc. Common stock
APREStock
$0.69−57.15%52W
Market Cap$8.61M
P/E—
Div yield—
Beta-1.26
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-28.81%
Price vs S&P 500 (4W)4.66%
VGM Score16.68
Market Capitalization$8.61M
Earnings Surprise History
Q1 26-0.22est. -0.23
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.22
4.22
4.30
4.30
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APREAprea Therapeutics, Inc. Common stock | — | F | D | $0.69 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies based on synthetic lethality. Its lead program, ATRN-119, is a small-molecule ATR inhibitor in clinical development for solid tumors. The company is also advancing APR-1051, an oral WEE1 inhibitor that recently entered clinical trials.